Endothelial progenitor cells mobilization after maximal exercise according to heart failure severity

doi:10.4330/wjc.v12.i11.526

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8776)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

379

WORD

219

HTML

3651

Figures (1-2)

413

Tables (1-4)

369

Sum=5031

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

381

Download

1025

Sum=1406

Publishing Process of This Article

Item

Count

Browse

596

Download

1743

Sum=2339

Nov 26, 2020 (publication date) through Mar 8, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Cardiol. Nov 26, 2020; 12(11): 526-539
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.526

Table 1 Demographic characteristics and maximal cardiopulmonary exercise testing indices of patients with chronic heart failure of different severity based on peak oxygen uptake

Demographic characteristics	Group 1	Group 2
Patients, n	25	24
Gender, males/females	21/4	20/4
Age in yr¹	57 ± 10	55 ± 9
Height in cm¹	174 ± 11	175 ± 9
Weight in kg¹	92 ± 25	87 ± 21
NYHA stage, class II/III	16/9	18/6
EF, %¹	32 ± 9	32 ± 8
Type of CHF
Dilated cardiomyopathy, n (%)	7 (28)	5 (21)
Ischemic, n (%)	14 (56)	15 (63)
Other, i.e. valvulopathy, etc., n (%)	4 (16)	4 (17)
Medication
Diuretics, n (%)	19 (76)	13 (54)
ACE inhibitors, n (%)	11 (44)	13 (54)
ARBs, n (%)	5 (20)	2 (8)
β-Blockers, n (%)	25 (100)	23 (96)
Aldosterone antagonists, n (%)	19 (76)	18 (75)
Cardiopulmonary exercise testing parameters
Peak VO₂ in mL/kg/min¹	14.5 ± 2.5	21.8 ± 2.4^a
Predicted peak VO₂, %¹	52 ± 13	74 ± 11^a
VE/VCO2 slope¹	34 ± 5	33 ± 4
Peak WR in watts¹	75 ± 34	118 ± 34^a

Group 1: Peak VO₂ < 18.0 mL/kg/min, Group 2: Peak VO₂ ≥ 18.0 mL/kg/min.

¹Values are expressed as mean ± SD; Difference between the 2 severity groups for demographic characteristics and cardiopulmonary exercise testing parameters (^aP < 0.05). ACE: Angiotensin-converting-enzyme; ARB: Angiotensin II receptor blockers; CPET: Cardiopulmonary exercise testing; CHF: Chronic heart failure; EF: Ejection fraction; NYHA: New York Heart Association; VCO₂: Carbon dioxide output; VO₂: Oxygen uptake; WR: Work rate.

Table 2 Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of two different severity groups according to the median value of peak oxygen uptake

Endothelial cellular populations	Group 1 of n = 25, peak VO₂ < 18.0 mL/kg/min		Group 2 of n = 24, peak VO₂ ≥ 18.0 mL/kg/min		P value between groups
Endothelial cellular populations	Before CPET	After CPET	Before CPET	After CPET	P value between groups
CD34⁺/CD45^-/CD133⁺	60 (25-76)	90 (70-103)^e	42 (19-73)	90 (39-118)^e	0.329
CD34⁺/CD45^-/CD133⁺/VEGFR₂	1 (1-4)	5 (3-8)^e	2 (1-3)	6 (3-9)^e	0.075
CD34⁺/CD133⁺/VEGFR₂	13 (9-17)	13 (9-26)	10 (7-18)	14 (10-19)^b	0.257
CD34⁺/CD45^-/CD133^-	186 (141-361)	488 (247-658)^e	218 (158-247)	311 (254-569)^e	0.101
CD34⁺/CD45^-/CD133^-/VEGFR₂	2 (1-2)	3 (2-5)^e	1 (1-2)	4 (2-6)^e	0.471

Difference within each severity group.

^bP < 0.01.

^eP < 0.001. CPET: Cardiopulmonary exercise testing; VO₂: Oxygen uptake.

Table 3 Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of different severity groups according to the median value of ventilation/carbon dioxide output slope

Endothelial cellular populations	Group 1 of n = 27, VE/VCO₂ slope < 32.5		Group 2 of n = 22, VE/VCO₂ slope ≥ 32.5		P value between groups
Endothelial cellular populations	Before CPET	After CPET	Before CPET	After CPET	P value between groups
CD34⁺/CD45^-/CD133⁺	62 (41-81)	95 (81-118)^e	31 (18-66)	70 (33-99)^e	0.711
CD34⁺/CD45^-/CD133⁺/VEGFR₂	1 (1-3)	5 (3-8)^e	2 (1-4)	5 (3-8)^e	0.311
CD34⁺/CD133⁺/VEGFR₂	10 (7-16)	13 (10-18)	12 (8-18)	16 (9-29)^b	0.134
CD34⁺/CD45^-/CD133^-	222 (147-287)	419 (267-576)^e	198 (152-376)	382 (249-794)^e	0.540
CD34⁺/CD45^-/CD133^-/VEGFR₂	1 (1-2)	3 (2-5)^e	1 (1-2)	4 (3-6)^e	0.464

Differences within each severity group.

^bP < 0.01.

^eP < 0.001. CPET: Cardiopulmonary exercise testing.

Table 4 Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of two different severity groups according to reduced or mid-ranged ejection fraction

Endothelial cellular populations	Group 1 of n = 37, EF < 40%		Group 2 of n = 12, EF ≥ 40%		P value between groups
Endothelial cellular populations	Before CPET	After CPET	Before CPET	After CPET	P value between groups
CD34⁺/CD45^-/CD133⁺	42 (22-75)	90 (37-106)^e	63 (40-76)	90 (65-103)^b	0.888
CD34⁺/CD45^-/CD133⁺/VEGFR₂	2 (1-3)	5 (3-8)^e	2 (1-4)	8(4-8)^b	0.507
CD34⁺/CD133⁺/VEGFR₂	11 (7-17)	14 (10-23)^b	15 (9-20)	13 (9-22)	0.473
CD34⁺/CD45^-/CD133^-	200 (152-279)	427 (260-626)^e	227 (135-372)	336 (214-624)^b	0.702
CD34⁺/CD45^-/CD133^-/VEGFR₂	1 (1-2)	3 (2-6)^e	1 (1-2)	3 (2-5)^b	0.828

Differences within each severity group.

^bP < 0.01.

^eP < 0.001. CPET: Cardiopulmonary exercise testing; EF: Ejection fraction.

Citation: Kourek C, Karatzanos E, Psarra K, Georgiopoulos G, Delis D, Linardatou V, Gavrielatos G, Papadopoulos C, Nanas S, Dimopoulos S. Endothelial progenitor cells mobilization after maximal exercise according to heart failure severity. World J Cardiol 2020; 12(11): 526-539
URL: https://www.wjgnet.com/1949-8462/full/v12/i11/526.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i11.526